Table 1.
Patient demographics and clinical characteristics (N = 366)
| Cases | % | Controls | % | ||
|---|---|---|---|---|---|
| Patients | 146 | 220 | |||
| Age (years) | Median | 67 | 65 | ||
| Range | 32–84 | 22–88 | |||
| Gender | M | 68 | 46 | 125 | 57 |
| F | 78 | 54 | 95 | 43 | |
| Primary tumour location | Colon | 47 | 32 | 89 | 40 |
| Gastric | 44 | 30 | 43 | 20 | |
| Rectum | 19 | 13 | 29 | 13 | |
| Pancreas | 10 | 7 | 15 | 7 | |
| Anus | 8 | 5 | 9 | 4 | |
| Breast | 4 | 3 | 9 | 4 | |
| Oesophagus | 4 | 3 | 6 | 3 | |
| Bile duct | 3 | 2 | 10 | 5 | |
| Head and neck | 3 | 2 | 7 | 3 | |
| Uterine cervix | 2 | 1 | 3 | 1 | |
| Vulvar | 2 | 1 | 0 | 0 | |
| Stage | I–III | 88 | 60 | 132 | 60 |
| IV | 58 | 40 | 88 | 40 | |
| Treatment setting | Neoadjuvant | 11 | 7 | 23 | 10 |
| Neoadjuvant + Adjuvant | 6 | 4 | 11 | 5 | |
| Adjuvant | 71 | 49 | 98 | 45 | |
| Metastatic | 58 | 40 | 88 | 40 | |
| Chemotherapy regimen | FU or Cape ± TT | 15 | 10 | 32 | 15 |
| FU or Cape + OXA ± TT | 74 | 50 | 110 | 50 | |
| FU or Cape + IRI ± TT | 4 | 3 | 6 | 3 | |
| FU or Cape + OXA + IRI ± TT | 6 | 4 | 12 | 5 | |
| FU or Cape + DDP ± TT | 16 | 11 | 10 | 4.5 | |
| FU or Cape + DDP/OXA + TXT | 11 | 8 | 19 | 9 | |
| FU or Cape + mitomycin C | 7 | 5 | 9 | 4 | |
| FU or Cape + gemcitabine | 9 | 6 | 12 | 5 | |
| FU or Cape ± others | 4 | 3 | 10 | 4.5 |
Others = anthracyclines, cyclophosphamide, nab-paclitaxel, vinorelbine.
FU 5-fluouracil, Cape capecitabine, TT (target therapy) cetuximab or bevacizumab or trastuzumab, OXA oxaliplatin, DDP cisplatin, IRI irinotecan, TXT taxanes (paclitaxel, docetaxel)